They are a purpose-driven biotechnology company committed to democratizing healthcare across the globe. Their vision is to disrupt the existing treatment paradigm for chronic diseases, increasingly dominated by drugs, particularly monoclonal antibodies (“mAbs”), which suffer from prohibitive costs and cumbersome administration. They believe their synthetic peptide vaccine platform (“Vaxxine Platform”) has the potential to enable a new class of therapeutics that will improve the quality and convenience of care, reduce costs and increase access to treatments for a wide range of indications. Their Vaxxine Platform is designed to harness the immune system to convert the body into its own “drug factory,” stimulating the production of antibodies with a therapeutic or protective effect. Their current pipeline consists of five chronic disease product candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s Disease (“AD”), Parkinson’s Disease (“PD”), migraine and hypercholesterolemia. Additionally, they believe their Vaxxine Platform may be used to disrupt the treatment paradigm for a wide range of other chronic diseases, including any that are or could potentially be successfully treated by mAbs. They also will opportunistically pursue infectious disease treatments.

Industry
Pharmaceutical Preparations

CEO	CFO
-

Employees	Founded
75	2014

Contacts

Address: 1717 Main St, Ste 3388 Dallas, Tx 75201

Telephone: (254) 244-5739

Web page: http://www.vaxxinity.com

IPO information

First Trade Date	11/11/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

Shares & Volumes

Shares Initial (MM)	6.7
Shares Revised (MM)	6
Expected offer amount (MM)	$100.5
Realized offer amount(MM)	$78

Financial Data (last reporting year)

Market Cap (MM)	$1673.7
Revenues (MM)	$0.13
Net Income (Loss) (MM)	$-87.8

Voting

What do you think will happen with the VAXX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes:

The lead left underwriter: BofA Securities

IPOs led by the firm	.Pro
Profitability of conducted IPOs ?	.Pro
1st day change ?	.Pro
Change for the first 3 months ?	.Pro

Underwriters
BofA Securities/ Jefferies/ Evercore ISI
CO-Managers
-

Sector: Healthcare

Tweets about $VAXX

Tweets
Tweets volume

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats

Interest over time
Interest by region

Vaxxinity, Inc. (VAXX)

Buy Bitcoin

Free full financial analysis

IPO Pro-version